| Lung Cancer Treatments and Mutations | Lifetime | 167 | US 98 | 99.54 |
| Cancer Genomics and Diagnostics | Lifetime | 272 | US 166 | 99.45 |
| Sarcoma Diagnosis and Treatment | Lifetime | 171 | US 93 | 99.19 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 363 | US 197 | 99.14 |
| Colorectal Cancer Treatments and Studies | Lifetime | 267 | US 123 | 99.11 |
| Cancer Mechanisms and Therapy | Lifetime | 150 | US 76 | 98.33 |
| Melanoma and MAPK Pathways | Lifetime | 119 | US 66 | 98.54 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 623 | US 280 | 98.57 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 234 | US 141 | 97.92 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 795 | US 327 | 97.90 |
| CAR-T cell therapy research | Lifetime | 645 | US 383 | 98.23 |
| Cancer-related Molecular Pathways | Lifetime | 804 | US 415 | 97.40 |
| Lung Cancer Research Studies | Lifetime | 727 | US 310 | 97.60 |
| Thyroid Cancer Diagnosis and Treatment | Lifetime | 459 | US 168 | 97.50 |
| Advanced Breast Cancer Therapies | Lifetime | 420 | US 195 | 96.64 |
| Fibroblast Growth Factor Research | Lifetime | 350 | US 153 | 95.24 |
| Cardiac tumors and thrombi | Lifetime | 828 | US 382 | 93.59 |
| Artificial Intelligence in Healthcare and Education | Lifetime | 663 | US 241 | 89.17 |
| Vascular Tumors and Angiosarcomas | Lifetime | 941 | US 419 | 90.01 |
| Cancer Genomics and Diagnostics | 2021-2025 | 5 | US 3 | 99.93 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 14 | US 4 | 99.92 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 32 | US 10 | 99.47 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 21 | US 8 | 99.70 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 4 | US 4 | 98.84 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 120 | US 46 | 99.53 |
| Cancer Mechanisms and Therapy | 2021-2025 | 19 | US 2 | 97.90 |
| Melanoma and MAPK Pathways | 2021-2025 | 15 | US 3 | 99.36 |
| Fibroblast Growth Factor Research | 2021-2025 | 11 | US 8 | 98.58 |
| Lung Cancer Research Studies | 2021-2025 | 86 | US 34 | 98.73 |
| Cancer-related Molecular Pathways | 2021-2025 | 33 | US 18 | 97.21 |
| Thyroid Cancer Diagnosis and Treatment | 2021-2025 | 83 | US 33 | 97.30 |
| CAR-T cell therapy research | 2021-2025 | 356 | US 202 | 97.62 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 135 | US 49 | 96.90 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 495 | US 96 | 96.64 |
| Advanced Breast Cancer Therapies | 2021-2025 | 152 | US 56 | 97.37 |
| Cancer Research and Treatments | 2021-2025 | 126 | US 37 | 93.41 |
| BRCA gene mutations in cancer | 2021-2025 | 162 | US 76 | 94.39 |
| Peptidase Inhibition and Analysis | 2021-2025 | 256 | US 78 | 94.51 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 313 | US 67 | 94.67 |
| HER2/EGFR in Cancer Research | 2021-2025 | 234 | US 84 | 96.33 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 448 | US 149 | 93.43 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 393 | US 101 | 92.53 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 656 | US 152 | 88.94 |
| Ethics in Clinical Research | 2021-2025 | 169 | US 68 | 90.78 |
| PARP inhibition in cancer therapy | 2021-2025 | 323 | US 123 | 90.56 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 495 | US 310 | 88.28 |
| Phagocytosis and Immune Regulation | 2021-2025 | 227 | US 75 | 82.73 |
| Protein Degradation and Inhibitors | 2021-2025 | 1,000 | US 420 | 84.13 |
| Health and Medical Research Impacts | 2021-2025 | 263 | US 154 | 80.50 |
| Cancer Diagnosis and Treatment | 2021-2025 | 810 | US 203 | 75.65 |
| Bone Tumor Diagnosis and Treatments | 2021-2025 | 674 | US 200 | 78.32 |
| Biomedical Ethics and Regulation | 2021-2025 | 569 | US 228 | 65.67 |
